TY  - GEN
AU  - Wells,Samuel A
AU  - Gosnell,Jessica E
AU  - Gagel,Robert F
AU  - Moley,Jeffrey
AU  - Pfister,David
AU  - Sosa,Julie A
AU  - Skinner,Michael
AU  - Krebs,Annetta
AU  - Vasselli,James
AU  - Schlumberger,Martin
TI  - Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer
SN  - 1527-7755
PY  - 2010///0304
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Biomarkers, Tumor
KW  - blood
KW  - Calcitonin
KW  - Carcinoembryonic Antigen
KW  - Carcinoma, Medullary
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - France
KW  - Genetic Predisposition to Disease
KW  - Germ-Line Mutation
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Pedigree
KW  - Piperidines
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Mas
KW  - Proto-Oncogene Proteins c-ret
KW  - antagonists & inhibitors
KW  - Quinazolines
KW  - Risk Factors
KW  - Thyroid Neoplasms
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2009.23.6604
ER  -